Company / SG&A Expense
Vanda Pharmaceuticals Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$112.9M
FY2025
5-year range
$112.9M / $140.5M
FY2021-FY2025
Trend
-17.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $85M in FY2017 to $141M in FY2022.
Based on SEC 10-K filings.
$113M in FY2025 with a 5-year CAGR of +1.3%.
Improved from $124M to $113M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -7.0%
- 5-Year CAGR
- +1.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +1.3%, indicating consistent growth.
- In FY2025, sg&a expense decreased 17.3% year-over-year.
- Peak sg&a expense was recorded in FY2022.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.9M | -17.3% |
| FY2024 | $136.5M | +10.0% |
| FY2023 | $124.0M | -11.7% |
| FY2022 | $140.5M | +8.3% |
| FY2021 | $129.7M | +22.7% |
| FY2020 | $105.8M | -14.6% |
| FY2019 | $123.8M | +24.1% |
| FY2018 | $99.8M | +18.0% |
| FY2017 | $84.5M | -0.1% |
| FY2016 | $84.6M | +237.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026